TFX Teleflex Incorporated

Teleflex continues to deliver COMPLETE confidence with new Arrow® ErgoPack® Complete MAC, PSI Systems

Teleflex continues to deliver COMPLETE confidence with new Arrow® ErgoPack® Complete MAC, PSI Systems

Teleflex expands value of ErgoPack® Complete enhancements to critical vascular access products

WAYNE, Pa., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) continues to deliver COMPLETE confidence with the release of the Arrow® ErgoPack® Complete Multi-Lumen Access Catheter (MAC) System and the Arrow® ErgoPack® Complete Percutaneous Sheath Introducer (PSI) System.

The release of the ErgoPack® Complete MAC and PSI Systems follows the release of the Arrow® ErgoPack® Complete CVC System in October 2020.

Teleflex conducted extensive research with industry-leading vascular access professionals to select the enhancements in the new ErgoPack® Complete MAC and PSI Systems. Clinician-inspired updates to the kit include:

  • The Arrow® GlideWheel™ Advancer, designed for tactile feedback and finer control
  • Nitinol Guidewire, which is kink-resistant compared to stainless steel
  • Transducer Cover to support guidelines for ultrasound use
  • Pre-filled sterile saline syringes inside the kit
  • Extra ChloraPrep® Skin Prep in each kit (two total)

“We’re proud to bring the clinician-focused enhancements of the ErgoPack® Complete System to our trusted MAC and PSI vascular access portfolios,” said Jake Newman, Group President, Teleflex Interventional and Vascular. “We’re committed to finding new customer-inspired ways to deliver proven solutions that reduce catheter-related complications for patients and the providers that serve them.”

These new additions enhance the already-considerable power of the ErgoPack® System, which feature, at its heart, Teleflex’s Arrowg+ard Blue® MAC and PSI catheters.

High-flow Arrow® MAC Catheters are designed to meet the needs of a variety of patient types – from trauma to cardiac - and offer full-spectrum antimicrobial protection against gram-positive, and gram-negative bacteria and fungi, the key infectious pathogens responsible for CLABSI. Arrow® PSI Catheters are designed to provide antimicrobial protection and optimal access for hemodynamic monitoring.

The ErgoPack® Complete System’s unique combination of MAC and PSI insertion components, packaged in an ergonomic and efficient top down, left to right configuration, helps central line inserters comply with critical third party independent guidelines for reducing CLABSI, including:

  • Centers for Disease Control and Prevention (CDC) Category 1A & 1B recommendations1
  • Society for Hospital Epidemiology of America (SHEA) Guidelines2
  • Infusion Nursing Society (INS) Standards of Practice3
  • Occupational Health and Safety Administration (OSHA) Bloodborne Pathogens Standard4

The ErgoPack® Complete MAC and PSI Systems are available in two different configurations, in a variety of catheter French sizes.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit .

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift®, and Weck® – trusted brands united by a common sense of purpose.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

Rx only

Contraindication:

The Arrowg+ard Blue® MAC and Arrowg+ard Blue® PSI are contraindicated for patients with known hypersensitivity to chlorhexidine and silver sulfadiazine and/or sulfa drugs.

Teleflex, the Teleflex logo, Arrow, Arrowg+ard Blue, Deknatel, ErgoPack, GlideWheel, Hudson RCI, LMA, Pilling, Rusch, UroLift, and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. All other marks are the property of their respective owners.

© 2020 Teleflex Incorporated. All rights reserved. MC-006901

References:

  1. O’Grady NP, Alexander M, Burns LA, et al. Guidelines for the Prevention of Intravascular Catheter-Related Infections, 2011 (Revised 2017). 2. Atlanta, GA: Centers for Disease Control and Prevention; 2017.
  2. Marschall J, Mermel LA, Fakih M, et al. Strategies to Prevent Central Line–Associated Bloodstream Infections in Acute Care Hospitals: 2014 Update. Infection Control and Hospital Epidemiology. 2014 July; 35(7): 753-71.
  3. Gorski L, Hadaway L, Hagle ME, McGoldrick M, et al. Infusion Therapy Standards of Practice. Journal of Infusion Nursing. 2016; Jan 39(1S).
  4. Occupational Safety & Health Administration Regulations (Standards – 29 CFR). Part 1910.1030: Bloodborne pathogens. Occupational Safety & Health Administration Web site. /laws-regs/regulations/standardnumber/1910/1910.1030. Accessed on February 12, 2020.

Source:

Teleflex Incorporated

Jake Elguicze

Treasurer and Vice President, Investor Relations

610-948-2836



EN
19/01/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Teleflex Incorporated

 PRESS RELEASE

Teleflex Announces First Quarter 2024 Earnings Conference Call Informa...

Teleflex Announces First Quarter 2024 Earnings Conference Call Information WAYNE, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its first quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, May 2, 2024. To participate in the conference call, please utilize this to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company’s website, . An audio replay of the call will be available beginning at 11:00 am Easte...

 PRESS RELEASE

Teleflex Incorporated Introduces the UroLift™ 2 System With Advanced T...

Teleflex Incorporated Introduces the UroLift™ 2 System With Advanced Tissue Control, a Revolutionary Unified Platform Designed to Treat All Prostate Types WAYNE, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- (NYSE:TFX), a leading global provider of medical technologies, today announced the upcoming full market release of the Advanced Tissue Control (ATC) feature on its unified UroLift™ 2 System platform designed for the treatment of benign prostatic hyperplasia (BPH) symptoms in men with all prostate types up to 100g. The UroLift™ 2 System with Advanced Tissue Control (UroLift™ 2 ATC) has rece...

 PRESS RELEASE

Teleflex’s Climate Targets Validated by the Science Based Targets Init...

Teleflex’s Climate Targets Validated by the Science Based Targets Initiative Teleflex commits to reach net-zero greenhouse gas emissions across its value chain by 2050. WAYNE, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced its near- and long-term climate change targets have been validated by the Science Based Targets initiative (SBTi). The announcement comes ahead of the company’s release of its 2023 Global Impact Report, which will be published in May 2024. Teleflex has responded to the SBTi...

 PRESS RELEASE

Teleflex Announces Quarterly Dividend

Teleflex Announces Quarterly Dividend WAYNE, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable March 15, 2024, to shareholders of record at the close of business on March 1, 2024. Additional information about Teleflex can be obtained from the company’s website at . About Teleflex Incorporated Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. W...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch